GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Asset Turnover

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Galmed Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Galmed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $17.13 Mil. Therefore, Galmed Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Galmed Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -54.81%. It is also linked to ROA % through Du Pont Formula. Galmed Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -47.07%.


Galmed Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Galmed Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Asset Turnover Chart

Galmed Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galmed Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galmed Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Galmed Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Asset Turnover falls into.



Galmed Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Galmed Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (16.561+16.629)/ 2 )
=0/16.595
=0.00

Galmed Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (17.638+16.629)/ 2 )
=0/17.1335
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Galmed Pharmaceuticals  (NAS:GLMD) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Galmed Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-8.064/14.713
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.064 / 0)*(0 / 17.1335)*(17.1335/ 14.713)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1645
=ROA %*Equity Multiplier
=-47.07 %*1.1645
=-54.81 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Galmed Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-8.064/17.1335
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-8.064 / 0)*(0 / 17.1335)
=Net Margin %*Asset Turnover
= %*0
=-47.07 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Galmed Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Headlines